NCT06508931View on ClinicalTrials.gov

Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With Relapsed or Refractory B-Cell Neoplasms

PHASE2RecruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

August 4, 2025

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2029

Conditions
B-Cell Neoplasm
Interventions
DRUG

zamtocabtagene autoleucel (MB-CART2019.1)

Tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy.

Trial Locations (1)

94805

RECRUITING

Institut Gustave Roussy, Villejuif

Sponsors
All Listed Sponsors
collaborator

PPD, Part of Thermo Fisher Scientific

INDUSTRY

lead

Miltenyi Biomedicine GmbH

INDUSTRY